Journal: Journal of the American College of Cardiology

Article Title: Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.

PMID/MRN: 27816552

Publication Date: 2016-Nov-02

Abstract:

Left atrial appendage closure (LAAC) using the Watchman device was FDA-approved as a stroke prevention alternative to warfarin for patients with non-valvular atrial fibrillation. However, clinical decision-making is confounded by the fact that while LAAC avoids the anticoagulant-related lifetime risk of bleeding, implantation is associated with up-front complications. Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as the therapy is introduced beyond the clinical trial sites into general clinical practice. To evaluate the acute procedural performance and complication rates for all Watchman cases performed in the US since FDA approval. In the absence of a formal national clinical registry since regulatory approval in March 2015, we obtained procedural data on Watchman implantation procedures. Briefly, every LAAC procedure requires the presence of a manufacturer clinical specialist, and procedural parameter and peri-procedural complication data are collected using a standardized process and forms. In 3,822 consecutive cases, implantation was successful in 3,653 (95.6%) with a median procedure time of 50 min (range 10, 210); implanting physicians performing these procedures (n=382) included 71% new, non-clinical trial implanters, performing 50% of the procedures. Procedural complication rates included: 39 pericardial tamponades (1.02%; 24 treated percutaneously, 12 surgically and 3 fatal), three procedure-related strokes (0.078%), 9 device embolizations (0.24%; 6 requiring surgical removal), and 3 procedure-related deaths (0.078%). Despite a large fraction of previously-inexperienced operators, in the real-world post-FDA approval experience of Watchman LAAC, procedural success was high and complication rates low. Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.